The Creek laboratory at Monash Institute of Pharmaceutical Sciences uses advanced metabolomics and systems pharmacology to investigate drug action in pathogens
The latest paper from our lab identified extracellular metabolites of Pseudomonas aeruginosa correlated with ceftolozane/tazobactam-resistant subpopulations and modelled the time-courses of these metabolites @JessTait_PKPD @CreekLab@CRE_RESPONDjournals.asm.org/doi/10.1128…
@CreekLab & MIPS team introduces Orbitrap Astral MS for faster throughput, higher sensitivity, & deeper proteome coverage. Supported by a $3m grant from the Medical Research Future Fund, the platform fosters collabs among institutions & industry partners.
monash.edu/pharm/about/news/…
Honoured to be awarded @arc_gov_au future fellowship #FT22 to study malaria parasite metabolism!!! This is only possible thanks to my amazing team and many collaborators. @MIPS_Australia#GlobalHealthTPA
#ASP2022@G__Siddiqui from @CreekLab just gave an excellent talk about their synthetic ozonides target ID chemoproteomics pulldown and how the drugs perturbed parasite redox homeostasis!
Agreed. Well done to Stanley, @LeannTilley and the whole team. Glad to contribute our 2c on metabolite ID, but happier to see how industry and academia can work together to discover new malaria drugs (with a cool mode of action)
A #proteomics resource to aid research of parasite biology, pathogenesis, and drug and vaccine discovery in malaria. A new mass spectral library for high-coverage and reproducible analysis of the Plasmodium falciparum–infected red blood cell proteome doi.org/10.1093/gigascience/…